|
0
|
|
Future-proofing tuberculosis therapy: framework for concurrent drug and resistance testing development.
(linkinghub.elsevier.com)
|
Saluzzo F
…
Cirillo DM
Lancet Infectious Diseases
2026-06-01
|
#amr
#susceptibility
#surveillance
#diagnostics
#tb
|
|
0
|
|
Transcription attenuation amplifies collateral vulnerabilities in rifampicin-resistant Mycobacterium tuberculosis.
(nature.com)
|
Eckartt KA
…
Rock JM
Nature Microbiology
2026-06-01
|
#amr
#metabolism
#virulence
#transcriptomics
#tb
|
|
0
|
|
Immediate or high-dose antituberculosis therapy for HIV-related sepsis in Tanzania and Uganda (ATLAS): a phase 3, open-label, randomised, controlled, 2 x 2 factorial, superiority trial.
(linkinghub.elsevier.com)
|
Heysell SK
…
Moore CC
Lancet Infectious Diseases
2026-06-01
|
#infection
#sepsis
#hiv
#mortality
#tb
|
|
0
|
|
Lipid accumulation in tuberculosis granulomas inhibits macrophage-CD4(+) T cell interactions and infection control.
(nature.com)
|
Chai Q
…
Liu CH
Nature Microbiology
2026-06-01
|
#infection
#metabolism
#immunity
#transcriptomics
#tb
|
|
0
|
|
Characteristics of Plausible Source Cases Responsible for Recent Mycobacterium tuberculosis Transmission, United States, 2018-2022.
(wwwnc.cdc.gov)
|
Kammerer S
…
Talarico S
Emerging Infectious Diseases
2026-06-01
|
#infection
#epidemiology
#transmission
#genotyping
#tb
|
|
0
|
|
Fomite transmission of Mycobacterium abscessus between severely disabled patients.
(linkinghub.elsevier.com)
|
Yoshida S
…
Nakamura S
Clinical Microbiology and Infection
2026-06-01
|
#genomics
#infection
#transmission
#nosocomial
#tb
|